Facebook Pixel A clear derating | Business Standard - newspaper - Lee esta historia en Magzter.com

Intentar ORO - Gratis

A clear derating

Business Standard

|

March 10, 2026

Markets risk underperformance if we don’t regain our growth credentials

A clear derating

If we look at data from January 1, 2025, to the end of February 2026, 14 months of heightened global volatility, we see some interesting trends. This period is before the Iran war and thus not affected by recent developments. Looking at exchange-traded funds as the barometer of individual market returns, we see that this has been a time of strong financial returns. Emerging market (EM) equities were up 51.4 percent, international equities were up by 47 per cent, the United States rose by 18.4 per cent, and total world equity returns were 28.3 per cent.

In contrast, over this same 14 months period, India was down 0.7 per cent, the second-worst performing market in the world, with only Saudi Arabia performing worse. In fact, India and Saudi Arabia are the only two markets that are actually down (all returns in US dollar). This is when Korea has tripled, Brazil is up 80 percent, and Taiwan has risen by more than 50 percent.

We have underperformed the EM benchmark by 5,000 basis points in just 14 months. Being overweight India has been a career finishing move! In this context, one can understand why nearly every foreign fund is currently underweight the country.

Absolute foreign ownership of the Indian market is at a 15-year low, and we see foreign portfolio investors (FPIs) selling on a daily basis. India has received zero net foreign flows over the last five years, a very long time indeed. What are some lessons from this period of unprecedented Indian underperformance?

MÁS HISTORIAS DE Business Standard

Business Standard

Nalco urges Odisha govt to expedite land handover process for ‘30K cr projects

Navratna central public-sector enterprise (CPSE) Nalco has requested the Odisha government to expedite the land handover process for its 30,000 crore expansion projects that will boost capacity and help it achieve the Maharatna status by 2030.

time to read

1 mins

March 10, 2026

Business Standard

Women-led startups saw 9% funding drop in 2025

Female labour participation just 42%, among lowest in G20: Axis Bank study

time to read

3 mins

March 10, 2026

Business Standard

Business Standard

How India can kick the West Asian oil habit

Increasing the use of alternative fuels like ethanol could be one way out

time to read

6 mins

March 10, 2026

Business Standard

India’s T20 WC win brings new stars to brand crease

\"Sachin Tendulkar carried Indian cricket on his shoulders for 21 years.

time to read

3 mins

March 10, 2026

Business Standard

UBS downgrades OMCs as oil crosses $100/bbl

The recent rally in crude prices and refining margins create a sense of déjà vu, UBS said, mirroring the 2022 oil market disruption.

time to read

1 min

March 10, 2026

Business Standard

LIC drove 18% rise in life insurers’ NBP in Feb

New business premium of life insurance companies grew 18 per cent year-on-year (Y-o-Y) to ₹35,417 crore in February, driven by robust growth at the state-owned Life Insurance Corporation of India (LIC) due to a favourable base.

time to read

1 mins

March 10, 2026

Business Standard

Why India needs Russian oil

India's oil security is becoming increasingly fragile. Over 80 per cent of its crude imports come from just two suppliers — West Asia and Russia — both now facing geopolitical stress. In this environment, resuming full purchases of Russian oil may not be a choice but a necessity. Here are eight reasons why.

time to read

3 mins

March 10, 2026

Business Standard

India, Uzbekistan launch pharma-nutra corridor

India and Uzbekistan on Monday launched a structured pharmaceutical and nutraceutical trade corridor aimed at expanding access to the Commonwealth of Independent States (CIS) and the wider Eurasian healthcare market, estimated at $7-10 billion.

time to read

1 min

March 10, 2026

Business Standard

Business Standard

A clear derating

Markets risk underperformance if we don’t regain our growth credentials

time to read

5 mins

March 10, 2026

Business Standard

Delhi HC allows Dr Reddy’s to make semaglutide for export

A division Bench of the Delhi High Court on Monday affirmed a single-judge Bench’s order allowing pharmaceutical company Dr Reddy’s Laboratories to manufacture the diabetes and weight-management drug semaglutide in India for export to jurisdictions where Danish drugmaker Novo Nordisk does not have patent protection.

time to read

2 mins

March 10, 2026

Listen

Translate

Share

-
+

Change font size